Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Takao Yamori

Showing results (1-10 of 161) with videos related to

Pageof 17
Sort By:
Gan to Kagaku Ryoho. Cancer & Chemotherapy|April 30, 2004
[Chemical evaluation by cancer cell line panel and its role in molecular target-based anticancer drug screening]Takao Yamori
Cancer Chemotherapy and Pharmacology|June 24, 2003
Panel of human cancer cell lines provides valuable database for drug discovery and bioinformaticsTakao Yamori
Tanpakushitsu Kakusan Koso. Protein, Nucleic Acid, Enzyme|December 7, 2007
[Cancer cell informatics and chemical biology]Takao Yamori
Proteome Science|April 1, 2009
Proteomic analysis of phosphoproteins sensitive to a phosphatidylinositol 3-kinase inhibitor, ZSTK474, by using SELDI-TOF MSTetsuyuki Akashi, Takao Yamori
Nihon Rinsho. Japanese Journal of Clinical Medicine|June 12, 2010
[Kinase inhibitors]Takao Yamori, Dexin Kong
Current Medicinal Chemistry|August 20, 2009
Advances in development of phosphatidylinositol 3-kinase inhibitorsDexin Kong, Takao Yamori
Proteomics|June 16, 2007
A novel method for analyzing phosphoproteins using SELDI-TOF MS in combination with a series of recombinant proteinsTetsuyuki Akashi, Takao Yamori
Clinical Pharmacology in Drug Development|October 15, 2019
Possible Contribution of Drug Approval Summaries Published by Drug Regulatory Authorities on Scientific Discussion and Drug DevelopmentKeiji Tanese, Takao Yamori
Cancer Science|July 12, 2008
Phosphatidylinositol 3-kinase inhibitors: promising drug candidates for cancer therapyDexin Kong, Takao Yamori
Cancer Science|August 23, 2007
ZSTK474 is an ATP-competitive inhibitor of class I phosphatidylinositol 3 kinase isoformsDexin Kong, Takao Yamori
Pageof 17

Showing results (1-10 of 161) with videos related to

Sort By:
Pageof 17
Gan to Kagaku Ryoho. Cancer & Chemotherapy|April 30, 2004
[Chemical evaluation by cancer cell line panel and its role in molecular target-based anticancer drug screening]Takao Yamori
Cancer Chemotherapy and Pharmacology|June 24, 2003
Panel of human cancer cell lines provides valuable database for drug discovery and bioinformaticsTakao Yamori
Tanpakushitsu Kakusan Koso. Protein, Nucleic Acid, Enzyme|December 7, 2007
[Cancer cell informatics and chemical biology]Takao Yamori
Proteome Science|April 1, 2009
Proteomic analysis of phosphoproteins sensitive to a phosphatidylinositol 3-kinase inhibitor, ZSTK474, by using SELDI-TOF MSTetsuyuki Akashi, Takao Yamori
Nihon Rinsho. Japanese Journal of Clinical Medicine|June 12, 2010
[Kinase inhibitors]Takao Yamori, Dexin Kong
Current Medicinal Chemistry|August 20, 2009
Advances in development of phosphatidylinositol 3-kinase inhibitorsDexin Kong, Takao Yamori
Proteomics|June 16, 2007
A novel method for analyzing phosphoproteins using SELDI-TOF MS in combination with a series of recombinant proteinsTetsuyuki Akashi, Takao Yamori
Clinical Pharmacology in Drug Development|October 15, 2019
Possible Contribution of Drug Approval Summaries Published by Drug Regulatory Authorities on Scientific Discussion and Drug DevelopmentKeiji Tanese, Takao Yamori
Cancer Science|July 12, 2008
Phosphatidylinositol 3-kinase inhibitors: promising drug candidates for cancer therapyDexin Kong, Takao Yamori
Cancer Science|August 23, 2007
ZSTK474 is an ATP-competitive inhibitor of class I phosphatidylinositol 3 kinase isoformsDexin Kong, Takao Yamori
Pageof 17